Last reviewed · How we verify
Stromal Vasular Fraction
Stromal Vasular Fraction is a Biologic drug developed by Antria. It is currently in Phase 2 development. Also known as: Stromal Vascular Fraction, Adiployx.
Stromal Vascular Fraction is a type of cell therapy derived from autologous adipose tissue. It is used to treat conditions such as keloids, and its mechanism of action is through cell-based interventions.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Stromal Vasular Fraction |
|---|---|
| Also known as | Stromal Vascular Fraction, Adiployx |
| Sponsor | Antria |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Autologous Adipose Derived Stem Cells Transplantation in the Treatment of Keloids. (PHASE2)
- Efficacy of Adipose Derived Stromal Vascular Fraction in the Treatment of Keloids (PHASE2)
- Stromal Vascular Fraction From Lipoaspirate to Treatment of Chronic Non-healing Wound (PHASE1)
- Adipose Derived Stem Cells in Facial Fat Grafting (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Stromal Vasular Fraction CI brief — competitive landscape report
- Stromal Vasular Fraction updates RSS · CI watch RSS
- Antria portfolio CI
Frequently asked questions about Stromal Vasular Fraction
What is Stromal Vasular Fraction?
Who makes Stromal Vasular Fraction?
Is Stromal Vasular Fraction also known as anything else?
What development phase is Stromal Vasular Fraction in?
Related
- Manufacturer: Antria — full pipeline
- Also known as: Stromal Vascular Fraction, Adiployx
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing